Intravenous bisphosphonates for postmenopausal osteoporosis

Journal of Research in Medical Sciences1735-199515320100104Intravenous bisphosphonates for postmenopausal osteoporosis175184ENMD, Department of Internal Medicine, Isfahan University of Medical Sciences2009072320091124<ul><li><h3 style="text-align: justify; direction: ltr; unicode-bidi: embed;">Abstract</h3></li><li>Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the suboptimal therapeutic compliance in postmenopausal women, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women .These preparations would become an option for patients who can not tolerate oral BPs or it was ineffective in increasing their bone density.<strong></strong></li><li>This article proposed to review effectiveness and tolerability of intravenous BPs in postmenopausal women with osteoporosis.</li><li><strong><span style="font-size: 8pt;">KEYWORDS:</span></strong> Bisphosphonates, Postmenopausal, Osteoporosis, Pamidronate, Ibandronate, Zoledronic Acid.</li></ul>  http://jrms.mui.ac.ir/index.php/jrms/article/view/4022http://jrms.mui.ac.ir/index.php/jrms/article/download/4022/1913